dm+d
Unassigned
New Medicines
Alzheimer's disease - prevention in cognitively healthy subjects that are genetically predisposed to the disease
Information
New molecular entity
Roche
Roche
Development and Regulatory status
None
None
Phase II Clinical Trials
Category
Anti-amyloid-beta (Aβ) monoclonal antibody
Alzheimers disease is the most common form of dementia, accounting for 50%-60% of all cases. The prevalence of dementia is below 1% in individuals aged 60-64 years, but shows an almost exponential increase with age, so that in people aged 85 years or older the prevalence is between 24% and 33% in the Western world.
Alzheimer's disease - prevention in cognitively healthy subjects that are genetically predisposed to the disease
also IV infusion
Subcutaneous injection